GFAP and Alzheimer disease: In the subgroup of p-tau217 positive AD patients, the vaccine generated efficacy signals in preserving cognition (CDR-SB), reducing biomarkers for neurodegeneration and neuroinflammation (plasma NfL and GFAP), and slowing brain atrophy.